hABT1: A Potential Drug Target for Alzheimer's Disease (G29777)

Target Name: ABT1

NCBI ID: G29777

ABT1

hABT1: A Potential Drug Target for Alzheimer's Disease

ABT1, or hABT1, is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the huntingtin gene family, which is a family of transmembrane proteins that are involved in a wide range of cellular processes, including neurotransmission and stress response.

Recent studies have identified hABT1 as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. This is because hABT1 has been shown to be overexpressed in the brains of individuals with Alzheimer's disease, and hABT1 knockdown has been shown to protect against the development of memory loss in animal models of Alzheimer's disease.

In addition to its potential as a drug target, hABT1 has also been identified as a biomarker for the early detection of Alzheimer's disease. Studies have shown that hABT1 levels are significantly decreased in the brains of individuals with Alzheimer's disease, and that hABT1 levels can be increased using techniques such as RNA interference or immunoprecipitation. These findings suggest that hABT1 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

While further research is needed to fully understand the role of hABT1 in Alzheimer's disease and its potential as a drug target, the study of hABT1 is an important step in the development of new treatments for this debilitating and terminal disease.

Protein Name: Activator Of Basal Transcription 1

Functions: Could be a novel TATA-binding protein (TBP) which can function as a basal transcription activator. Can act as a regulator of basal transcription for class II genes (By similarity)

The "ABT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets